Pittrow D, Krappweis J, Kirch W
Institut für Klinische Pharmakologie, BMBF Forschungsverbund Public Health Sachsen 01EG 94314, Medizinische Fakultät, Technische Universität Dresden.
Dtsch Med Wochenschr. 2002 Sep 27;127(39):1995-2000. doi: 10.1055/s-2002-34355.
Only a few studies have been done in Germany on the use of drugs in homes for the elderly and nursing homes. This is the first retrospective and longitudinal pharmaco-epidemiological study comparing the pattern of drug prescriptions for patients in nursing or for-the-elderly homes with that for health-insured ambulant patients or those not requiring care, all of them of the same age-group.
The samples were taken from a cohort of 3592 members of a company health insurance in Berlin, aged 60 years or over (912 men, 2680 women) who had been insured throughout 1999. The insurance company's database provided anonymous information on the insured and their doctors, details of drug prescriptions and hospital treatment. The patients were divided into three groups, group A: all those requiring care who lived in homes for the elderly or nursing homes (n=996); group B: all ambulant patients receiving care (n=1603), and group C: patients not requiring care, matched to the other groups for age and sex (n=993). All drugs were classified according to the anatomical-therapeutic-chemical WHO codes and listed by defined daily dosage (DDD).
Those in group A received on average 3.6 DDD daily, those of group B 4.6 DDD, and those of group C 3.0 DDD. The relevant cost was 714 Euro (group A), 1126 Euro (group B) and 539 Euro (group C) per person in 1999. Indications of inadequate treatment concerned the use of psychopharmaceuticals (neuroleptics, antidepressives, hypnotics), analgesics, digitalis glycosides, antidiabetic drugs, diuretics, laxatives, and drugs of unproven efficacy. 15% of home residents received prescription from doctors on emergency call. These drugs were often continued beyond the immediate treatment.
These data provide evidence of the lacking quality in the drug treatment of the elderly.
在德国,针对养老院和护理院用药情况的研究较少。这是第一项回顾性纵向药物流行病学研究,比较了养老院或老年护理院患者与参保门诊患者或无需护理患者(年龄组相同)的用药处方模式。
样本取自柏林一家公司健康保险的3592名成员队列,年龄在60岁及以上(男性912名,女性2680名),他们在1999年全年参保。保险公司数据库提供了参保人员及其医生的匿名信息、药物处方细节和住院治疗情况。患者分为三组,A组:所有住在养老院或护理院的需要护理的患者(n = 996);B组:所有接受护理的门诊患者(n = 1603),C组:无需护理的患者,按年龄和性别与其他组匹配(n = 993)。所有药物均根据世界卫生组织解剖治疗化学代码分类,并按限定日剂量(DDD)列出。
A组患者平均每日接受3.6 DDD药物,B组为4.6 DDD,C组为3.0 DDD。1999年人均相关费用分别为A组714欧元、B组1126欧元和C组539欧元。治疗不足的指征涉及精神药物(抗精神病药、抗抑郁药、催眠药)、镇痛药、洋地黄苷、抗糖尿病药、利尿剂、泻药以及疗效未经证实的药物。15%的居家居民接受了出诊医生的处方。这些药物往往在即时治疗后仍继续使用。
这些数据证明了老年人药物治疗质量的欠缺。